Chemical Therapeutics
VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer
Stefan Hart, Veronica Novotny-Diermayr, Kee Chuan Goh, Meredith Williams, Yong Cheng Tan, Lai Chun Ong, Albert Cheong, Bee Kheng Ng, Chithra Amalini, Babita Madan, Harish Nagaraj, Ramesh Jayaraman, Khalid M. Pasha, Kantharaj Ethirajulu, Wee Joo Chng, Nurulhuda Mustafa, Boon Cher Goh, Cyril Benes, Ultan McDermott, Mathew Garnett, Brian Dymock and Jeanette M. Wood
Stefan Hart
Authors' Affiliations: S*BIO Pte Ltd.; Cancer Science Institute of Singapore, National University of Singapore; Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore, Singapore; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts; and Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
Veronica Novotny-Diermayr
Authors' Affiliations: S*BIO Pte Ltd.; Cancer Science Institute of Singapore, National University of Singapore; Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore, Singapore; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts; and Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
Kee Chuan Goh
Authors' Affiliations: S*BIO Pte Ltd.; Cancer Science Institute of Singapore, National University of Singapore; Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore, Singapore; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts; and Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
Meredith Williams
Authors' Affiliations: S*BIO Pte Ltd.; Cancer Science Institute of Singapore, National University of Singapore; Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore, Singapore; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts; and Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
Yong Cheng Tan
Authors' Affiliations: S*BIO Pte Ltd.; Cancer Science Institute of Singapore, National University of Singapore; Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore, Singapore; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts; and Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
Lai Chun Ong
Authors' Affiliations: S*BIO Pte Ltd.; Cancer Science Institute of Singapore, National University of Singapore; Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore, Singapore; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts; and Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
Albert Cheong
Authors' Affiliations: S*BIO Pte Ltd.; Cancer Science Institute of Singapore, National University of Singapore; Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore, Singapore; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts; and Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
Bee Kheng Ng
Authors' Affiliations: S*BIO Pte Ltd.; Cancer Science Institute of Singapore, National University of Singapore; Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore, Singapore; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts; and Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
Chithra Amalini
Authors' Affiliations: S*BIO Pte Ltd.; Cancer Science Institute of Singapore, National University of Singapore; Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore, Singapore; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts; and Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
Babita Madan
Authors' Affiliations: S*BIO Pte Ltd.; Cancer Science Institute of Singapore, National University of Singapore; Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore, Singapore; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts; and Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
Harish Nagaraj
Authors' Affiliations: S*BIO Pte Ltd.; Cancer Science Institute of Singapore, National University of Singapore; Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore, Singapore; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts; and Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
Ramesh Jayaraman
Authors' Affiliations: S*BIO Pte Ltd.; Cancer Science Institute of Singapore, National University of Singapore; Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore, Singapore; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts; and Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
Khalid M. Pasha
Authors' Affiliations: S*BIO Pte Ltd.; Cancer Science Institute of Singapore, National University of Singapore; Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore, Singapore; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts; and Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
Kantharaj Ethirajulu
Authors' Affiliations: S*BIO Pte Ltd.; Cancer Science Institute of Singapore, National University of Singapore; Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore, Singapore; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts; and Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
Wee Joo Chng
Authors' Affiliations: S*BIO Pte Ltd.; Cancer Science Institute of Singapore, National University of Singapore; Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore, Singapore; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts; and Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United KingdomAuthors' Affiliations: S*BIO Pte Ltd.; Cancer Science Institute of Singapore, National University of Singapore; Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore, Singapore; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts; and Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
Nurulhuda Mustafa
Authors' Affiliations: S*BIO Pte Ltd.; Cancer Science Institute of Singapore, National University of Singapore; Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore, Singapore; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts; and Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
Boon Cher Goh
Authors' Affiliations: S*BIO Pte Ltd.; Cancer Science Institute of Singapore, National University of Singapore; Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore, Singapore; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts; and Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
Cyril Benes
Authors' Affiliations: S*BIO Pte Ltd.; Cancer Science Institute of Singapore, National University of Singapore; Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore, Singapore; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts; and Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
Ultan McDermott
Authors' Affiliations: S*BIO Pte Ltd.; Cancer Science Institute of Singapore, National University of Singapore; Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore, Singapore; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts; and Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
Mathew Garnett
Authors' Affiliations: S*BIO Pte Ltd.; Cancer Science Institute of Singapore, National University of Singapore; Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore, Singapore; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts; and Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
Brian Dymock
Authors' Affiliations: S*BIO Pte Ltd.; Cancer Science Institute of Singapore, National University of Singapore; Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore, Singapore; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts; and Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
Jeanette M. Wood
Authors' Affiliations: S*BIO Pte Ltd.; Cancer Science Institute of Singapore, National University of Singapore; Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore, Singapore; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts; and Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
DOI: 10.1158/1535-7163.MCT-12-0466 Published February 2013

Article Information
Volume 12, Issue 2, pp. 151-161
PubMed
Published By
Print ISSN
Online ISSN
History
- Received May 14, 2012
- Revision received December 13, 2012
- Accepted December 17, 2012
- Published first December 27, 2012.
Article Versions
- Previous version (December 27, 2012 - 14:39).
- Previous version (January 31, 2013 - 14:04).
- You are viewing the most recent version of this article.
Copyright & Usage
©2012 American Association for Cancer Research.
Author Information
- Stefan Hart1,
- Veronica Novotny-Diermayr1,
- Kee Chuan Goh1,
- Meredith Williams1,
- Yong Cheng Tan1,
- Lai Chun Ong1,
- Albert Cheong1,
- Bee Kheng Ng1,
- Chithra Amalini1,
- Babita Madan1,
- Harish Nagaraj1,
- Ramesh Jayaraman1,
- Khalid M. Pasha1,
- Kantharaj Ethirajulu1,
- Wee Joo Chng2,3,
- Nurulhuda Mustafa2,
- Boon Cher Goh2,
- Cyril Benes4,
- Ultan McDermott5,
- Mathew Garnett5,
- Brian Dymock1, and
- Jeanette M. Wood1
- Authors' Affiliations: 1S*BIO Pte Ltd.; 2Cancer Science Institute of Singapore, National University of Singapore; 3Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore, Singapore; 4Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts; and 5Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
- Corresponding Author:
Stefan Hart, S*BIO Pte Ltd., 1 Science Park Road, #05-09 The Capricorn, Singapore 117528, Singapore. Phone: 65-6645-3412; Fax: 65-6225-4654; E-mail: stefan.sbio{at}gmail.com
February 2013
Volume 12, Issue 2
Volume 12, Issue 2
VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer
Stefan Hart, Veronica Novotny-Diermayr, Kee Chuan Goh, Meredith Williams, Yong Cheng Tan, Lai Chun Ong, Albert Cheong, Bee Kheng Ng, Chithra Amalini, Babita Madan, Harish Nagaraj, Ramesh Jayaraman, Khalid M. Pasha, Kantharaj Ethirajulu, Wee Joo Chng, Nurulhuda Mustafa, Boon Cher Goh, Cyril Benes, Ultan McDermott, Mathew Garnett, Brian Dymock and Jeanette M. Wood
Mol Cancer Ther February 1 2013 (12) (2) 151-161; DOI: 10.1158/1535-7163.MCT-12-0466
VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer
Stefan Hart, Veronica Novotny-Diermayr, Kee Chuan Goh, Meredith Williams, Yong Cheng Tan, Lai Chun Ong, Albert Cheong, Bee Kheng Ng, Chithra Amalini, Babita Madan, Harish Nagaraj, Ramesh Jayaraman, Khalid M. Pasha, Kantharaj Ethirajulu, Wee Joo Chng, Nurulhuda Mustafa, Boon Cher Goh, Cyril Benes, Ultan McDermott, Mathew Garnett, Brian Dymock and Jeanette M. Wood
Mol Cancer Ther February 1 2013 (12) (2) 151-161; DOI: 10.1158/1535-7163.MCT-12-0466
Jump to section
Advertisement